Tetracycline hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for tetracycline hydrochloride and what is the scope of patent protection?
Tetracycline hydrochloride
is the generic ingredient in fourteen branded drugs marketed by Avet, Bristol, Warner Chilcott, Pharmacia And Upjohn, Solvay, Wyeth Ayerst, Apothecon, Angus, Abbott, Amneal Pharms Ny, Ani Pharms, Aurobindo Pharma Usa, Breckenridge, Chartwell Tetra, Elkins Sinn, Esjay Pharma, Ferrante, Heather, Hikma, Impax Labs, Ivax Sub Teva Pharms, Mast Mm, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Superpharm, Valeant Pharm Intl, Watson Labs, Pfipharmecs, Schiff And Co, Shire, Lederle, Pfizer, Storz, Endo Operations, Alpharma Us Pharms, Proter, and Strides Pharma, and is included in fifty-three NDAs. Additional information is available in the individual branded drug profile pages.There are forty-nine drug master file entries for tetracycline hydrochloride. Eight suppliers are listed for this compound.
Summary for tetracycline hydrochloride
US Patents: | 0 |
Tradenames: | 14 |
Applicants: | 39 |
NDAs: | 53 |
Drug Master File Entries: | 49 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Clinical Trials: | 227 |
What excipients (inactive ingredients) are in tetracycline hydrochloride? | tetracycline hydrochloride excipients list |
DailyMed Link: | tetracycline hydrochloride at DailyMed |
Recent Clinical Trials for tetracycline hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mahidol Oxford Tropical Medicine Research Unit | Phase 2/Phase 3 |
Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | Phase 2/Phase 3 |
Universidade Federal do Para | Phase 3 |
Pharmacology for tetracycline hydrochloride
Drug Class | Tetracycline-class Antimicrobial |
Anatomical Therapeutic Chemical (ATC) Classes for tetracycline hydrochloride
US Patents and Regulatory Information for tetracycline hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Elkins Sinn | TETRACYCLINE HYDROCHLORIDE | tetracycline hydrochloride | CAPSULE;ORAL | 060059-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Hikma | TETRACYCLINE HYDROCHLORIDE | tetracycline hydrochloride | CAPSULE;ORAL | 060768-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Pharmacia And Upjohn | PANMYCIN | tetracycline hydrochloride | CAPSULE;ORAL | 060347-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Tetracycline hydrochloride Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.